Journal of Clinical Medicine (Jan 2022)

History of Heart Failure in Patients Hospitalized Due to COVID-19: Relevant Factor of In-Hospital Complications and All-Cause Mortality up to Six Months

  • Mateusz Sokolski,
  • Konrad Reszka,
  • Tomasz Suchocki,
  • Barbara Adamik,
  • Adrian Doroszko,
  • Jarosław Drobnik,
  • Joanna Gorka-Dynysiewicz,
  • Maria Jedrzejczyk,
  • Krzysztof Kaliszewski,
  • Katarzyna Kilis-Pstrusinska,
  • Bogusława Konopska,
  • Agnieszka Kopec,
  • Anna Larysz,
  • Weronika Lis,
  • Agnieszka Matera-Witkiewicz,
  • Lilla Pawlik-Sobecka,
  • Marta Rosiek-Biegus,
  • Justyna M. Sokolska,
  • Janusz Sokolowski,
  • Anna Zapolska-Tomasiewicz,
  • Marcin Protasiewicz,
  • Katarzyna Madziarska,
  • Ewa A. Jankowska

DOI
https://doi.org/10.3390/jcm11010241
Journal volume & issue
Vol. 11, no. 1
p. 241

Abstract

Read online

Background: Patients with heart failure (HF) are at high risk of unfavorable courses of COVID-19. The aim of this study was to evaluate characteristics and outcomes of COVID-19 patients with HF. Methods: Data of patients hospitalized in a tertiary hospital in Poland between March 2020 and May 2021 with laboratory-confirmed COVID-19 were analyzed. The study population was divided into a HF group (patients with a history of HF) and a non-HF group. Results: Out of 2184 patients (65 ± 13 years old, 50% male), 12% had a history of HF. Patients from the HF group were older, more often males, had more comorbidities, more often dyspnea, pulmonary and peripheral congestion, inflammation, and end-organ damage biomarkers. HF patients had longer and more complicated hospital stay, with more frequent acute HF development as compared with non-HF. They had significantly higher mortality assessed in hospital (35% vs. 12%) at three (53% vs. 22%) and six months (72% vs. 47%). Of 76 (4%) patients who developed acute HF, 71% died during hospitalization, 79% at three, and 87% at six months. Conclusions: The history of HF identifies patients with COVID-19 who are at high risk of in-hospital complications and mortality up to six months of follow-up.

Keywords